Condition: Non-squamous NSCLC · HER2 Exon 20 Mutation · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California - Irvine Medical Center | Orange, California, United States | — |
| University of California (UC) Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Florida Cancer Specialists South Divisio | Fort Myers, Florida, United States | — |
| Florida Cancer Specialists North Divisio | St. Petersburg, Florida, United States | — |
| University of Kansas Medical Center (KUMC) | Kansas City, Kansas, United States | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Gabrail Cancer Center | Canton, Ohio, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Summit Cancer Centers - North Spokane | Spokane, Washington, United States | — |
| Royal North Shore Hospital | St Leonards, Saint Leonards, Australia | — |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04447118